Mathews I I, Padmanabhan K P, Ganesh V, Tulinsky A, Ishii M, Chen J, Turck C W, Coughlin S R, Fenton J W
Department of Chemistry, Michigan State University, East Lansing 48824-1322.
Biochemistry. 1994 Mar 22;33(11):3266-79. doi: 10.1021/bi00177a018.
Many of the vital actions of thrombin on platelets and other cells appear to be mediated by the recently cloned seven-transmembrane-domain thrombin receptor. Thrombin activates this receptor by a novel proteolytic mechanism. The amino-terminal exodomain of the receptor contains the sequence LDPRSFLLRNPNDKYEPF. Structure-activity studies with mutant receptors and receptor peptides suggest that this sequence binds to thrombin at two sites: LDPR with the active center of thrombin and KYEPF with the fibrinogen recognition exosite of thrombin. Thrombin then cleaves the Arg41-Ser42 bond to unmask a new amino terminus, which functions as a tethered peptide ligand binding to as yet undefined sites within the body of the receptor to effect receptor activation. We have determined eight crystal structures of thrombin complexed with receptor-based peptides. Each of the two components of the bidentate docking model was captured in individual cocrystals. In one crystal type, the LDPR sequence docked in the active center of thrombin in a manner analogous to d-PheProArg chloromethyl ketone. In other crystals, the KYEPF sequence bound in the fibrinogen anion binding exosite of thrombin in a manner analogous to the DFEEI sequence of the carboxylate-terminal peptide of hirudin. Strikingly, however, generation of a single crystal that includes both components of the anticipated bidentate binding mode was not achieved, apparently because the peptides have a dominant solution S-like conformation that does not bind in a productive way at the active center. This peptide structure apparently favored a novel alternative mode of receptor peptide-thrombin interaction in which the receptor peptides formed an intermolecular bridge between neighboring thrombin molecules, resulting in an infinite peptide thrombin chain in crystals. In this structure, the KYEPF sequence docked in the expected manner at the exosite of one thrombin molecule, but the LDPR sequence docked in an unusual nonproductive mode with the active center of a neighboring molecule. Mutations that removed important determinants of the S-like receptor peptide structure underlying the bridging mode in the receptor itself did not significantly alter thrombin signaling. Additionally, a comparison of receptor density to the responsiveness of a cell did not support a role for receptor oligomerization in signaling. The physiological role for this unexpected intermolecular binding mode, if any, remains to be identified.(ABSTRACT TRUNCATED AT 400 WORDS)
凝血酶对血小板及其他细胞的许多重要作用似乎是由最近克隆出的七跨膜结构域凝血酶受体介导的。凝血酶通过一种新的蛋白水解机制激活该受体。受体的氨基末端胞外结构域包含序列LDPRSFLLRNPNDKYEPF。对突变受体和受体肽进行的结构 - 活性研究表明,该序列在两个位点与凝血酶结合:LDPR与凝血酶的活性中心结合,KYEPF与凝血酶的纤维蛋白原识别外位点结合。然后凝血酶切割Arg41 - Ser42键以暴露出一个新的氨基末端,该末端作为一种拴系肽配体,与受体内尚未明确的位点结合以实现受体激活。我们已确定了与基于受体的肽复合的凝血酶的八个晶体结构。双齿对接模型的两个组分各自在单独的共晶体中被捕获。在一种晶体类型中,LDPR序列以类似于d - PheProArg氯甲基酮的方式对接在凝血酶的活性中心。在其他晶体中,KYEPF序列以类似于水蛭素羧基末端肽的DFEEI序列的方式结合在凝血酶的纤维蛋白原阴离子结合外位点。然而,令人惊讶的是,并未获得包含预期双齿结合模式两个组分的单晶,显然是因为这些肽具有占主导地位的溶液S样构象,该构象不能以有效的方式在活性中心结合。这种肽结构显然有利于受体肽 - 凝血酶相互作用的一种新的替代模式,其中受体肽在相邻的凝血酶分子之间形成分子间桥,导致晶体中形成无限的肽 - 凝血酶链。在这种结构中,KYEPF序列以预期方式对接在一个凝血酶分子的外位点,但LDPR序列以一种不寻常的非有效模式与相邻分子的活性中心对接。去除受体自身中桥接模式所依赖的S样受体肽结构重要决定因素的突变并未显著改变凝血酶信号传导。此外,受体密度与细胞反应性的比较并不支持受体寡聚化在信号传导中的作用。这种意外的分子间结合模式的生理作用(如果有的话)仍有待确定。(摘要截短至400字)